1. Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
- Author
-
Said M, Omar H, Soliman Z, Saad Y, Dabes H, Hamed S, ElSaeed K, ElShazly Y, and ElSerafy M
- Subjects
- Adult, Aged, Anilides adverse effects, Antiviral Agents adverse effects, Carbamates adverse effects, Cyclopropanes, Drug Therapy, Combination, Egypt, Female, Genotype, Hepacivirus genetics, Hepatitis C, Chronic complications, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic virology, Humans, Lactams, Macrocyclic, Macrocyclic Compounds adverse effects, Male, Middle Aged, Proline analogs & derivatives, Prospective Studies, Recovery of Function, Renal Dialysis, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic therapy, Ribavirin adverse effects, Sulfonamides, Sustained Virologic Response, Time Factors, Treatment Outcome, Valine, Viral Load, Young Adult, Anilides therapeutic use, Antiviral Agents therapeutic use, Carbamates therapeutic use, Glomerular Filtration Rate, Hepacivirus drug effects, Hepatitis C, Chronic drug therapy, Kidney physiopathology, Macrocyclic Compounds therapeutic use, Renal Insufficiency, Chronic physiopathology, Ribavirin therapeutic use
- Abstract
Background: The present study aimed at evaluation of changes in estimated glomerular filtration rate (eGFR) among chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) Stages 3-5 who were treated with 12 weeks of ritonavir-boosted paritaprevir, ombitasvir plus ribavirin., Methods: Changes in renal functions were compared across follow up time points (baseline, SVR4, and SVR8). Data on on-treatment adverse events (AEs), serious AEs, laboratory abnormalities, treatment discontinuation were collected., Results: 171 patients were included (females 35%, mean age 53 years). 29 patients had liver cirrhosis. The most common etiologies of CKD were diabetes and/or hypertension (n = 67). All included patient reached the end of treatment (EOT) with no treatment discontinuations. The overall EOT response was 100%. 122/122 (100%) patients who reached 4 weeks post-treatment have achieved SVR4, and 80/80 (100%) have achieved SVR12. No reported SAEs. Ribavirin therapy was interrupted in 25% (43/171) of patients due to anemia; 16 patients required blood transfusions. The median eGFR improved from 33.5 (15) mL/min/1.73 m
2 at baseline to 35 (36) mL/min/1.73 m2 at SVR8 (p = 0.0003)., Conclusions: The use of ombitasvir, paritaprevir, and ritonavir for treatment of HCV-infected patients with advanced renal disease was safe and effective, moreover, it was associated with significantly improved eGFR.- Published
- 2019
- Full Text
- View/download PDF